Mark A. Bittinger
Impact in
- Genetics top 0.5%
- Glioma Diagnosis and Treatment
- Cancer Research top 0.5%
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
Papers in
- Oncology 9
- Cancer Immunotherapy and Biomarkers 7
- CAR-T cell therapy research 2
-
- Immune cells in cancer 3
- Immune Cell Function and Interaction 3
- Co-authors
- Shin-San Michael Su (3 shared papers)Stefan Größ (3 shared papers)Lenny Dang (3 shared papers)Shengfang Jin (3 shared papers)Valeria R. Fantin (3 shared papers)Edward M. Driggers (3 shared papers)Hyun Gyung Jang (3 shared papers)Joshua D. Rabinowitz (2 shared papers)
- Journals
- Cancer Immunology Research (3 papers)ACS Medicinal Chemistry Letters (2 papers)Nature (2 papers)PLoS ONE (2 papers)Molecular Pharmacology (1 paper)
- Partner nations
- United StatesCanadaTaiwan
In The Last Decade
Mark A. Bittinger
20 papers receiving 6.2k citations
Mark A. Bittinger's Hit Papers
Peers
Comparison fields: 5 of 113
- Genetics 1.8k
- Cancer Research 2.3k
- Hematology 694
- Molecular Biology 3.1k
- Oncology 1.0k
Countries citing papers authored by Mark A. Bittinger
This map shows the geographic impact of Mark A. Bittinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Bittinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Bittinger more than expected).
Fields of papers citing papers by Mark A. Bittinger
This network shows the impact of papers produced by Mark A. Bittinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Bittinger. The network helps show where Mark A. Bittinger may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark A. Bittinger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Hit paper breakdown → | 2009 | 3485 |
| 2 | Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations Hit paper breakdown → | 2010 | 621 |
| 3 | Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids Hit paper breakdown → | 2017 | 484 |
| 4 | 2010 | 453 | |
| 5 | 2011 | 271 | |
| 6 | 2004 | 201 | |
| 7 | 2019 | 122 | |
| 8 | 2016 | 110 | |
| 9 | 2003 | 100 | |
| 10 | 2018 | 77 | |
| 11 | 2016 | 65 | |
| 12 | 1997 | 58 | |
| 13 | 2017 | 45 | |
| 14 | 2021 | 43 | |
| 15 | 2021 | 35 | |
| 16 | 2000 | 34 | |
| 17 | 2020 | 30 | |
| 18 | 2016 | 26 | |
| 19 | 2015 | 24 | |
| 20 | 2020 | 23 |
About Mark A. Bittinger
Mark A. Bittinger is a scholar working on Oncology, Immunology, Genetics, Cancer Research and Molecular Biology, having authored 20 papers that have together received 6.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (7 papers), Glioma Diagnosis and Treatment (3 papers), Immune cells in cancer (3 papers), Cancer, Hypoxia, and Metabolism (3 papers), Immune Cell Function and Interaction (3 papers), CAR-T cell therapy research (2 papers), Occupational and environmental lung diseases (2 papers) and Signaling Pathways in Disease (2 papers). The work is most often cited by research in Genetics (1.8k citations), Cancer Research (2.3k citations), Hematology (694 citations), Molecular Biology (3.1k citations) and Oncology (1.0k citations). Mark A. Bittinger has collaborated with scholars based in United States, Canada and Taiwan. Frequent co-authors include Shin-San Michael Su, Stefan Größ, Lenny Dang, Shengfang Jin, Valeria R. Fantin, Edward M. Driggers, Hyun Gyung Jang, Joshua D. Rabinowitz, Kevin M. Marks and Craig B. Thompson. Their work appears in journals such as Cancer Immunology Research, ACS Medicinal Chemistry Letters, Nature, PLoS ONE and Molecular Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.